Department of Medicine, Cedars-Sinai Cancer, Los Angeles, CA.
Division of Urology, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA.
Oncology (Williston Park). 2021 Mar 15;35(3):119-125. doi: 10.46883/ONC.2021.3503.0119.
DNA-damage repair (DDR) pathway mutations can sensitize cancer cells to a class of cancer therapeutics known as PARP inhibitors. Given that DDR alterations can be found in up to one-third of advanced prostate cancers, PARP inhibitors have recently been established in treatment-refractory settings. We provide an updated review of the clinical data supporting the 4 PARP inhibitors that have undergone the most investigation thus far in metastatic castrate-resistant prostate cancer (mCRPC). Two of these agents are currently approved for the treatment of DDR-altered mCRPC. We end with a discussion on integration of approved PARP inhibitors into advanced prostate cancer clinical practice.
DNA 损伤修复 (DDR) 通路突变可使癌细胞对一类称为 PARP 抑制剂的癌症治疗药物敏感。鉴于 DDR 改变在多达三分之一的晚期前列腺癌中都能发现，PARP 抑制剂最近已在治疗抵抗的情况下确立。我们对支持迄今为止在转移性去势抵抗性前列腺癌 (mCRPC) 中接受最多研究的 4 种 PARP 抑制剂的临床数据进行了更新综述。其中两种药物目前被批准用于治疗 DDR 改变的 mCRPC。最后，我们讨论了将已批准的 PARP 抑制剂纳入晚期前列腺癌临床实践的问题。
